查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988220

性行为感染诊断市场：2026-2032年全球市场预测（依产品类型、诊断测试类型、病原体类型、检体类型、技术类型和最终用户类型划分）

Sexually Transmitted Disease Diagnostics Market by Product Types, Diagnostic Test Types, Pathogen Types, Sample Types, Technology Types, End-User Types - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，性行为感染传染病诊断市场价值将达到 1,194.2 亿美元，到 2026 年将成长至 1,267 亿美元，到 2032 年将达到 1,821.1 亿美元，复合年增长率为 6.21%。

主要市场统计数据
基准年 2025 1194.2亿美元
预计年份：2026年 1267亿美元
预测年份 2032 1821.1亿美元
复合年增长率 (%) 6.21%

简要概述技术创新、分散式医疗保健服务以及不断变化的临床重点如何重塑临床和公共卫生环境中的性行为感染(STI) 诊断。

性行为感染感染（STI）的诊断格局正经历快速的技术和营运变革，影响诊断服务提供者、检测网路、临床医生和公共卫生机构。分子技术、携带式检测平台和整合诊断工作流程的进步正在重塑感染疾病的检测方式、结果的沟通方式以及诊疗路径的建构方式。同时，强调分散式检查和提高患者自主性的诊疗模式的演变，推动了对就地检验和自测方案的需求，进而改变了采购、品质保证和监管方面的优先事项。

分子生物学、微流体和分散式护理模式的创新如何从根本上改变性行为感染感染 (STI) 的诊断和监测实践。

分子技术的突破、快速携带式检测技术的成熟以及先进生物资讯技术的引入，正在改变性行为感染（STI）的诊断格局。基于CRISPR的新型诊断方法以及核酸扩增技术的进步，包括PCR和次世代定序，正在提高更多病原体的检测灵敏度和特异性。同时，诸如采用微流体技术的晶片实验室解决方案和改进的侧向流动检测方法等先进的免疫检测技术，正在实现真正的即时检测（PoC）工作流程，从而在传统检查室之外提供可靠的检测结果。

评估美国于 2025 年实施的关税调整对性行为感染传染病 (STD) 诊断相关人员的实际供应链和采购影响。

美国2025年实施的关税政策对整个诊断供应链和采购管道产生了实际的营运和策略影响。进口设备、试剂和特殊组件的关税调整增加了许多供应商的收货成本，迫使製造商和经销商重新评估筹资策略、库存政策和定价模式。为此，一些企业正在加快本土化生产，实现供应商多元化，并探索替代组件供应商，以维持利润率并确保按时交货。

透过详细的細項分析，将诊断方式、目标病原体、最终用户环境、检体要求、平台技术和产品类型连结起来，并将其转化为可操作的市场洞察。

细分市场分析揭示了不同诊断方式、病原体标靶、终端用户环境、检体类型、技术平台和产品形式的需求驱动因素和技术适用性存在差异。根据诊断测试类型，临床检测仍然是高通量生物标记、血液和尿液检查检测工作流程的核心。同时，分子检测，例如次世代定序、核酸增幅检查和聚合酵素链锁反应(PCR)，为检测复杂病原体提供了黄金标准灵敏度。携带式分析仪、快速诊断测试和自我测试检测套组等即时检测形式正在扩大检测范围，但仍需进行严格的检验，以确保其准确性与临床检测方法相当。

对美洲、欧洲、中东和非洲以及亚太地区的区域趋势和基础设施进行考察，以了解影响诊断技术采用、取得和伙伴关係模式的因素。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的需求模式、监管要求和伙伴关係机会。在美洲，临床网路和公共卫生组织正在部署集中式和社区式检测相结合的方案，以解决在医疗服务取得和及时诊断方面持续存在的差距。同时，保险覆盖政策和不断变化的报销框架正在影响新型分子诊断和即时检测（POC​​）解决方案的普及速度。

竞争与合作策略，帮助企业在性行为感染(STI) 诊断领域取得竞争优势，结合平台整合、监管合规与创新技术合作。

企业层面的关键洞察聚焦于策略定位、产品组合广度和能力，这些要素能够在竞争激烈的诊断生态系统中实现差异化。领先的仪器製造商强调平台集成，支援多重检测，并提供可与实验室资讯系统整合的分析和自动化系统。试剂和试剂盒供应商专注于经过验证的、针对特异性病原体的细菌和病毒诊断检验，同时也在投资于供应链的稳健性和跨多个司法管辖区的监管註册。新兴企业优先发展颠覆性技术，例如基于 CRISPR 的检测方法、实验室晶片微流体和新型光谱学，并寻求临床检验伙伴关係和有针对性的试点部署，以建立信誉。

为製造商、检查室和公共卫生合作伙伴制定可操作的策略重点，以加速招募并建立强大的诊断业务。

产业领导者应推动一系列协调一致的倡议，以整合产品开发、监管策略、供应链韧性和经营模式，从而抓住新的机会。优先投资于兼具实验室级性能和分散式使用便利性的技术，使平台能够在医院、社区诊所和消费者环境中部署，同时确保临床完整性。同时，制定清晰的循证计划，重点关注实际应用效能、验证性检测途径和成本效益，以支持负责人和采购决策。

严谨的混合方法研究过程，结合对从业者的访谈、技术文献的回顾以及交叉检验的分析框架，确保了可靠的诊断见解。

本报告的调查方法结合了第一手和第二手调查，旨在全面了解性行为感染（ STI）诊断的现状。第一手调查包括对临床实验室主任、感染疾病专家、公共卫生官员和诊断行业高管进行结构化访谈和讨论，以了解当前的实践、推广应用的障碍以及战略重点。基于这些一线观点，我们对该技术的成熟度、营运限制以及在临床和消费者管道中的应用驱动因素进行了定性评估。

创新、营运韧性和策略合作是决定哪些诊断解决方案将在临床环境中广泛采用并实现公共卫生价值的整体观点。

总之，性行为感染（ STI）的诊断正处于一个转折点，随着技术进步、不断演进的医疗模式和供应链现状的交汇，临床工作流程和市场机会正在改变。分子检测、基于CRISPR的平台、微流体技术和先进免疫检测技术的创新，正在拓展集中式和分散式检查检查室环境的能力。因此，相关人员必须权衡快速、高灵敏度诊断的潜力与检验、监管合规以及整合到医疗路径中的实际挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依产品类型性行为感染感染诊断市场

  • 消耗品
    • 移液器
    • 管子
  • 装置
    • 分析器
    • 自动化系统
  • 试剂和试剂盒
    • 细菌性行为感染感染检测试剂盒
    • 病毒性性行为感染试剂盒

第九章：性行为感染感染诊断市场－依诊断检验类型划分

  • 临床试验
    • 基于生物标记的检测
    • 验血
    • 尿液检查
  • 分子检测
    • 次世代定序
    • 核酸增幅检查（NAAT）
    • 聚合酵素链锁反应（PCR）
  • 即时检测
    • 携带式分析设备
    • 快速诊断测试
    • 自测检测套组

第十章：以病原体分類的性行为感染感染诊断市场

  • 细菌性行为感染传染病
    • 披衣菌感染
    • 淋病
    • 梅毒
  • 霉菌性性行为感染感染
  • 寄生性行为感染传染病
  • 病毒性性性行为感染感染
    • B型肝炎
    • 单纯疱疹病毒
    • 人类免疫力缺乏病毒（HIV）
    • 人类乳突病毒（HPV）

第十一章：依检体类型分類的性行为感染感染诊断市场

  • 血液检体
    • 电浆
    • 血清
  • 拭子检体
    • 生殖器拭子
    • 口腔拭子
    • 直肠拭子
  • 尿液检体
    • 第一次尿液
    • 中段尿

第十二章：依技术类型分類的性行为感染感染诊断市场

  • 基于 CRISPR 的诊断方法
  • 免疫检测
    • ELISA
    • 横向流动化验
  • 微流体技术
  • 光谱学
    • 红外线的
    • 拉曼光谱

第十三章：依最终用户分類的性行为感染感染诊断市场

  • 诊断检查室
    • 病理检查室
    • 研究所
  • 居家照护设施
    • 消费者测试
    • 网路药房
  • 医院和诊所
    • 医疗设施
    • 门诊部
  • 公共卫生局
    • 社区健康中心
    • 州卫生部门

第十四章：性行为感染感染诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：性行为感染感染诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：性行为感染感染诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国性行为感染感染诊断市场

第十八章：中国性行为感染感染诊断市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Astra Biotech Gmbh
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • OraSure Technologies, Inc.
  • Qiagen Inc
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-6D54EA0F9447

The Sexually Transmitted Disease Diagnostics Market was valued at USD 119.42 billion in 2025 and is projected to grow to USD 126.70 billion in 2026, with a CAGR of 6.21%, reaching USD 182.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 119.42 billion
Estimated Year [2026] USD 126.70 billion
Forecast Year [2032] USD 182.11 billion
CAGR (%) 6.21%

A concise orientation to how technological innovation, decentralized care delivery, and changing clinical priorities are reshaping STD diagnostics across clinical and public health settings

The sexually transmitted disease diagnostics landscape is undergoing rapid technical and operational shifts that affect diagnostics providers, laboratory networks, clinical practitioners, and public health entities. Advances in molecular technologies, portable testing platforms, and integrated diagnostics workflows are reshaping how infections are detected, how results are delivered, and how care pathways are constructed. Meanwhile, evolving care models that emphasize decentralized testing and greater patient autonomy are increasing demand for point-of-care and self-testing options, which in turn changes procurement, quality assurance, and regulatory priorities.

Clinicians and public health leaders are adapting to changes in pathogen prevalence, the expanding scope of multiplex diagnostics, and the need for faster, actionable results to support treatment and contact tracing. Diagnostic manufacturers must navigate a complex array of sample types, including blood, various swabs, and urine, each with distinct pre-analytic and analytic requirements. At the same time, laboratory services are integrating automation, next-generation sequencing, and advanced immunoassays into workflows to improve throughput and diagnostic certainty. This introduction frames the remainder of the executive summary by outlining the intersecting drivers of innovation, the operational pressures shaping adoption, and the strategic questions leaders must address to remain competitive and clinically relevant.

How converging innovations in molecular biology, microfluidics, and decentralized care models are fundamentally altering STD diagnostics and surveillance practices

The landscape for sexually transmitted disease diagnostics is shifting in transformative ways, driven by breakthroughs in molecular techniques, the maturation of rapid and portable testing, and the incorporation of advanced bioinformatic methods. Emerging CRISPR-based diagnostics and improvements in nucleic acid amplification, including PCR and next-generation sequencing, are increasing sensitivity and specificity across a wider range of pathogens. Concurrently, microfluidic lab-on-a-chip solutions and refined immunoassays such as enhanced lateral flow formats are enabling true point-of-care workflows that deliver reliable results outside traditional laboratories.

These technical advances coincide with changes in care delivery. Home-based testing models and direct-to-consumer distribution channels are expanding patient access while introducing new considerations around result interpretation, confirmatory testing, and linkage to care. Diagnostic laboratories are responding by adopting automation and multiplex platforms that support high-throughput screening and comprehensive pathogen panels. Public health entities are leveraging interoperable data systems and genomic surveillance to monitor outbreaks and resistance patterns, which underscores the growing importance of integrating diagnostic outputs with epidemiologic intelligence. Together, these shifts are redefining competitive advantage, regulatory priorities, and partnership models across the diagnostics ecosystem.

Evaluating the practical supply chain and procurement consequences of the United States tariff adjustments enacted in 2025 on STD diagnostics stakeholders

United States tariff policies enacted in 2025 have introduced tangible operational and strategic implications across diagnostic supply chains and procurement channels. Tariff adjustments on imported instruments, reagents, and specialized components have increased landed costs for many suppliers, prompting manufacturers and distributors to reassess sourcing strategies, inventory policies, and pricing models. In response, several organizations have accelerated onshoring initiatives, diversified supplier bases, and explored alternative component suppliers to preserve margin and maintain delivery timelines.

These tariff-induced cost dynamics ripple through clinical and public health settings by influencing purchasing decisions for capital equipment and recurring consumables. Laboratories and hospitals are prioritizing total cost of ownership analyses and prioritizing platforms that consolidate test menus to reduce unit costs. Meanwhile, reagent and kit providers are re-evaluating distribution agreements and exploring regional manufacturing partnerships to mitigate customs complexity and tariff exposure. The net effect is a renewed emphasis on supply chain resilience, strategic supplier relationships, and procurement practices that balance cost containment with the imperative of maintaining diagnostic quality and continuity of patient care.

Deep segmentation intelligence that connects diagnostic modalities, pathogen targets, end-user settings, sample requirements, platform technologies, and product categories into actionable market implications

Segmentation insights reveal differentiated demand drivers and technology fit across diagnostic modalities, pathogen targets, end-user settings, sample types, technology platforms, and product forms. Based on diagnostic test types, laboratory tests remain central for high-throughput biomarker-based, blood, and urine testing workflows, while molecular tests such as next-generation sequencing, nucleic acid amplification tests, and polymerase chain reaction deliver gold-standard sensitivity for complex pathogen detection. Point-of-care formats including portable analyzers, rapid diagnostic tests, and self-test kits are expanding access but require careful validation to ensure parity with laboratory methods.

Pathogen-focused segmentation identifies distinct clinical and commercial priorities across bacterial infections like chlamydia, gonorrhea, and syphilis; viral infections including hepatitis B, herpes simplex, HIV, and HPV; parasitic causes such as trichomoniasis; and fungal conditions like candidiasis. End-user segmentation highlights that diagnostic laboratories, including pathology and research labs, prioritize throughput and multiplex capability, whereas home care channels, through direct-to-consumer testing and online pharmacies, emphasize ease of use and clear guidance for follow-up. Hospitals and clinics balance rapid turnaround with integration into electronic medical records, and public health departments require robust reporting and surveillance interoperability.

Sample-type segmentation underscores that blood-derived plasma and serum, swab collections from genital, oral, and rectal sites, and urine samples including first-catch and midstream variants each impose unique pre-analytic controls and kit design considerations. Technology segmentation shows the growing relevance of CRISPR-based diagnostics, immunoassays such as ELISA and lateral flow, lab-on-a-chip microfluidics, and spectroscopy techniques including infrared and Raman for adjunctive analysis. Product-type segmentation differentiates consumables like pipettes and tubes, instruments such as analyzers and automation systems, and reagents and kits tailored for bacterial versus viral diagnostics, each with distinct procurement cycles and regulatory pathways. These intersecting segmentation layers inform go-to-market strategies, clinical validation priorities, and product development roadmaps.

Regional dynamics and infrastructure considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence diagnostic adoption, access, and partnership models

Regional dynamics shape demand patterns, regulatory imperatives, and partnership opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas region, clinical networks and public health agencies are deploying a mix of centralized laboratory platforms and expanding community-based testing to address persistent gaps in access and timely diagnosis. Meanwhile, coverage policies and evolving reimbursement frameworks influence the adoption cadence for novel molecular and point-of-care solutions.

Across Europe, Middle East & Africa, heterogeneous regulatory regimes and varying laboratory infrastructure drive differential adoption of high-complexity assays versus decentralized rapid tests. Public health priorities in this region emphasize surveillance, antimicrobial resistance monitoring, and equitable access, which creates demand for robust, low-cost diagnostics with strong field performance. In the Asia-Pacific region, manufacturing capacity, a large and diverse patient base, and rapid uptake of digital health integrations support accelerated adoption of integrated diagnostic platforms and localized production of reagents and consumables. Collectively, these regional characteristics inform market entry strategies, distribution partnerships, and the localization of service and support capabilities to meet specific clinical and regulatory requirements.

Competitive and collaborative company strategies that combine platform consolidation, regulatory reach, and innovative tech partnerships to win in STD diagnostics

Key company-level insights focus on strategic positioning, portfolio breadth, and capabilities that enable differentiation in a competitive diagnostics ecosystem. Leading instrument manufacturers emphasize platform consolidation, providing analyzers and automation systems that support multiplex testing and integrate with laboratory information systems. Reagent and kit providers focus on validated, pathogen-specific assays for bacterial and viral diagnostics while investing in supply chain robustness and regulatory registrations across multiple jurisdictions. Emerging players prioritize disruptive technologies such as CRISPR-based assays, lab-on-a-chip microfluidics, and novel spectroscopy approaches, seeking clinical validation partnerships and targeted pilot deployments to build credibility.

Channel and service models are increasingly important differentiators. Companies that offer flexible procurement options, training and technical support, and data-management services that facilitate reporting to public health authorities tend to achieve higher adoption in institutional settings. At the same time, organizations that develop clear pathways for consumer-facing products, including support for confirmatory testing and linkage to care, are better positioned to capture demand in home testing channels. Strategic collaborations between established manufacturers and innovative startups, including co-development and distribution agreements, are accelerating the translation of novel diagnostics into scalable offerings while mitigating technical and regulatory risk.

Practical and actionable strategic priorities for manufacturers, laboratories, and public health partners to accelerate adoption and build resilient diagnostic businesses

Industry leaders should pursue a set of coordinated actions that align product development, regulatory strategy, supply chain resilience, and commercial models to capture emerging opportunities. Prioritize investments in technologies that bridge laboratory-grade performance with decentralized usability so that platforms can be deployed across hospitals, community clinics, and consumer settings while maintaining clinical integrity. Simultaneously, establish clear evidence-generation plans that emphasize real-world performance, confirmatory pathways, and cost-effectiveness to support payer and procurement decisions.

Strengthening supplier diversity and nearshoring components where feasible will reduce exposure to tariff volatility and improve responsiveness to demand surges. Develop tiered go-to-market approaches that tailor messaging and support to diagnostic laboratories, hospitals, public health departments, and home care channels, and create bundled service offerings that include training, integration support, and data reporting capabilities. Finally, pursue strategic partnerships with public health agencies, academic centers, and technology innovators to accelerate validation studies and expand surveillance applications, thereby reinforcing clinical credibility and creating pathways to long-term adoption.

A rigorous mixed-methods research process combining practitioner interviews, technical literature review, and cross-validated analytical frameworks to ensure robust diagnostic insights

The research methodology for this report combined primary and secondary approaches to develop a comprehensive view of the sexually transmitted disease diagnostics landscape. Primary research included structured interviews and consultations with clinical laboratory directors, infectious disease clinicians, public health officials, and diagnostic industry executives to capture current practices, barriers to adoption, and strategic priorities. These firsthand perspectives informed qualitative assessments of technology readiness, operational constraints, and adoption drivers across clinical and consumer channels.

Secondary research reviewed peer-reviewed literature, regulatory guidance documents, conference proceedings, and product technical specifications to validate technology descriptions, sample handling requirements, and regulatory pathways. Cross-validation between primary and secondary inputs ensured that conclusions reflect both practitioner experience and the technical evidence base. Analytical frameworks emphasized technology maturity, clinical utility, supply chain factors, and commercialization dynamics. Wherever possible, evidence was triangulated across multiple sources to reduce bias and increase the robustness of insights included in the report.

Summative perspectives on how innovation, operational resilience, and strategic collaboration will determine which diagnostic offerings gain clinical traction and public health value

In conclusion, sexually transmitted disease diagnostics are at an inflection point where technological advances, evolving care models, and supply chain realities intersect to redefine clinical workflows and market opportunities. Innovations in molecular testing, CRISPR-based platforms, microfluidics, and enhanced immunoassays are expanding the capabilities of both centralized laboratories and decentralized testing environments. As a result, stakeholders must balance the promise of rapid, sensitive diagnostics with the practicalities of validation, regulatory compliance, and integration into care pathways.

Leaders who proactively align product development with end-user needs, fortify supply chains against tariff and sourcing shocks, and create partnerships that bridge clinical, public health, and consumer contexts will be best positioned to translate technological promise into sustained clinical impact. The actions recommended in this summary provide a strategic foundation to guide investment, collaboration, and operational decisions that will shape the future of STD detection and management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexually Transmitted Disease Diagnostics Market, by Product Types

  • 8.1. Consumables
    • 8.1.1. Pipettes
    • 8.1.2. Tubes
  • 8.2. Instruments
    • 8.2.1. Analyzers
    • 8.2.2. Automation Systems
  • 8.3. Reagents and Kits
    • 8.3.1. Kits for Bacterial STDs
    • 8.3.2. Kits for Viral STDs

9. Sexually Transmitted Disease Diagnostics Market, by Diagnostic Test Types

  • 9.1. Laboratory Tests
    • 9.1.1. Biomarker-Based Tests
    • 9.1.2. Blood Tests
    • 9.1.3. Urine Tests
  • 9.2. Molecular Tests
    • 9.2.1. Next-Generation Sequencing
    • 9.2.2. Nucleic Acid Amplification Tests (NAATs)
    • 9.2.3. Polymerase Chain Reaction (PCR)
  • 9.3. Point-of-Care Tests
    • 9.3.1. Portable Analyzers
    • 9.3.2. Rapid Diagnostic Tests
    • 9.3.3. Self-Test Kits

10. Sexually Transmitted Disease Diagnostics Market, by Pathogen Types

  • 10.1. Bacterial STDs
    • 10.1.1. Chlamydia
    • 10.1.2. Gonorrhea
    • 10.1.3. Syphilis
  • 10.2. Fungal STDs
  • 10.3. Parasitic STDs
  • 10.4. Viral STDs
    • 10.4.1. Hepatitis B
    • 10.4.2. Herpes Simplex Virus
    • 10.4.3. Human Immunodeficiency Virus (HIV)
    • 10.4.4. Human Papillomavirus (HPV)

11. Sexually Transmitted Disease Diagnostics Market, by Sample Types

  • 11.1. Blood Samples
    • 11.1.1. Plasma
    • 11.1.2. Serum
  • 11.2. Swab Samples
    • 11.2.1. Genital Swabs
    • 11.2.2. Oral Swabs
    • 11.2.3. Rectal Swabs
  • 11.3. Urine Samples
    • 11.3.1. First Catch
    • 11.3.2. Midstream

12. Sexually Transmitted Disease Diagnostics Market, by Technology Types

  • 12.1. CRISPR-Based Diagnostics
  • 12.2. Immunoassays
    • 12.2.1. ELISA
    • 12.2.2. Lateral Flow Assays
  • 12.3. Microfluidics
  • 12.4. Spectroscopy
    • 12.4.1. Infrared
    • 12.4.2. Raman Spectroscopy

13. Sexually Transmitted Disease Diagnostics Market, by End-User Types

  • 13.1. Diagnostic Laboratories
    • 13.1.1. Pathology Laboratories
    • 13.1.2. Research Laboratories
  • 13.2. Home Care Settings
    • 13.2.1. Direct-to-Consumer Testing
    • 13.2.2. Online Pharmacies
  • 13.3. Hospitals and Clinics
    • 13.3.1. Healthcare Facilities
    • 13.3.2. Outpatient Clinics
  • 13.4. Public Health Departments
    • 13.4.1. Community Health Centers
    • 13.4.2. State Health Departments

14. Sexually Transmitted Disease Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexually Transmitted Disease Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexually Transmitted Disease Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Sexually Transmitted Disease Diagnostics Market

18. China Sexually Transmitted Disease Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Astra Biotech Gmbh
  • 19.7. Becton Dickinson and company
  • 19.8. Bio-Rad Laboratories, Inc.
  • 19.9. bioMerieux SA
  • 19.10. Danaher Corporation
  • 19.11. Daye Limited
  • 19.12. Diasorin S.p.A
  • 19.13. F. Hoffmann-La Roche Ltd
  • 19.14. Geneproof
  • 19.15. Hologic Inc.
  • 19.16. Jiangsu BioPerfectus Technologies Co., Ltd
  • 19.17. Liferiver Bio-Tech Corp.
  • 19.18. MedMira Inc
  • 19.19. Meridian Bioscience Inc.
  • 19.20. Mylab Discovery Solutions Pvt. Ltd.
  • 19.21. OraSure Technologies, Inc.
  • 19.22. Qiagen Inc
  • 19.23. Quest Consumer Inc.
  • 19.24. Sansure Biotech Inc.
  • 19.25. Seegene Inc.
  • 19.26. Siemens Healthcare GmbH
  • 19.27. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PIPETTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PIPETTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PIPETTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TUBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TUBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TUBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY KITS FOR BACTERIAL STDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY KITS FOR BACTERIAL STDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY KITS FOR BACTERIAL STDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY KITS FOR VIRAL STDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY KITS FOR VIRAL STDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY KITS FOR VIRAL STDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BIOMARKER-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SELF-TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL STDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC STDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SWAB SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SWAB SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SWAB SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY GENITAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ORAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ORAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ORAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RECTAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FIRST CATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FIRST CATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY FIRST CATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CRISPR-BASED DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CRISPR-BASED DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CRISPR-BASED DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SPECTROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INFRARED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INFRARED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INFRARED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAMAN SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAMAN SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RAMAN SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY STATE HEALTH DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SPECTROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TEST TYPES, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTS, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPES, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL STDS, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL STDS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY URINE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY TYPES, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY SPECTROSCOPY, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER TYPES, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPES, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA SEXUALLY TRANSMITTED DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)

TABLE